Phase 1
N=56
The Effects of Smell on Mood and Physical Responses
Stress · Anxiety · Depression
Bottom Line
View on ClinicalTrials.gov: NCT00097253 ↗Enrolled (actual)
56
Serious AEs
0.0%
Results posted
Feb 2010
Primary outcome: Primary: Cortisol and Catecholamine Production — 0.107; 0.119; 0.107; 43.5 pg/ml (log 10) — p=0.83
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Exposure to relaxant and stimulant odors (Behavioral)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- Primary completion
- Mar 2006
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cortisol and Catecholamine Production |
0.107; 0.119; 0.107; 43.5; 44.3; 38.3 | 0.83 |
| PRIMARY Immune Function |
3.706; 3.622; 3.623; 1.777; 1.734; 1.787 | 0.10 |
| PRIMARY Skin Barrier Repair |
23.21; 24.33; 22.11; 15.64; 17.78; 16.82 | 0.60 |
| PRIMARY Immune Function: Delayed Hypersensitivity to Candida(DTH) |
10.84; 17.39; 12.40 | 0.014 sig |
Summary
The purpose of this study is to examine the body's response to relaxing and stimulating fragrances commonly used in aromatherapy.
Eligibility Criteria
Inclusion Criteria
- Healthy adults with a normal sense of smell
Exclusion Criteria
- Treatment with medication that has immunological or endocrinological consequences
- Chronic health problems that affect immune or endocrine systems
- Allergy to perfume or cosmetics
- Problems with sense of smell
- Respiratory problems
- Smoker
- Current active asthma
- Use of psychoactive drugs or mood-altering medication
- History of anxiety disorder, major depression, bipolar disorder, schizophrenia, or other psychotic disorders
- History of chest pain or ventricular fibrillation
Data sourced from ClinicalTrials.gov (NCT00097253). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.